Badreddin Edris - Edgewise Therapeutics CoFounder Director
| EWTX Stock | USD 32.08 0.10 0.31% |
Insider
Badreddin Edris is CoFounder Director of Edgewise Therapeutics
| Age | 37 |
| Address | 1715 38th Street, Boulder, CO, United States, 80301 |
| Phone | 720 262 7002 |
| Web | https://www.edgewisetx.com |
Badreddin Edris Latest Insider Activity
Tracking and analyzing the buying and selling activities of Badreddin Edris against Edgewise Therapeutics stock is an integral part of due diligence when investing in Edgewise Therapeutics. Badreddin Edris insider activity provides valuable insight into whether Edgewise Therapeutics is net buyers or sellers over its current business cycle. Note, Edgewise Therapeutics insiders must abide by specific rules, including filing SEC forms every time they buy or sell Edgewise Therapeutics'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Badreddin Edris over two months ago Disposition of 3080 shares by Badreddin Edris of SpringWorks Therapeutics at 42.075 subject to Rule 16b-3 | ||
Badreddin Edris over three months ago Disposition of 385 shares by Badreddin Edris of SpringWorks Therapeutics at 42.0366 subject to Rule 16b-3 |
Edgewise Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.2236) % which means that it has lost $0.2236 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.319) %, meaning that it created substantial loss on money invested by shareholders. Edgewise Therapeutics' management efficiency ratios could be used to measure how well Edgewise Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.31 in 2024. Return On Capital Employed is likely to drop to -0.37 in 2024. Net Tangible Assets is likely to rise to about 418.7 M in 2024, whereas Total Assets are likely to drop slightly above 252.6 M in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| Lisa Miller | Lumos Pharma | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| RAC Sakai | Tempest Therapeutics | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Ramtin MD | RenovoRx | 58 | |
| Hing Wong | HCW Biologics | 70 | |
| MBA MD | Ikena Oncology | 59 | |
| Peter Rhode | HCW Biologics | 66 | |
| James Ahlers | RenovoRx | 60 | |
| Katherine Taudvin | Scpharmaceuticals | N/A | |
| BBA CPA | Lumos Pharma | 57 | |
| Richard Hawkins | Lumos Pharma | 75 | |
| Kristin Ainsworth | Seres Therapeutics | N/A | |
| Jennifer Schroeder | Ikena Oncology | N/A | |
| FACC FAHA | Milestone Pharmaceuticals | 66 | |
| Jeffrey Ecsedy | Ikena Oncology | 54 | |
| Angela Nelms | RenovoRx | 47 | |
| Kimberly Sheehan | Milestone Pharmaceuticals | N/A | |
Management Performance
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 |
Edgewise Therapeutics Leadership Team
Elected by the shareholders, the Edgewise Therapeutics' board of directors comprises two types of representatives: Edgewise Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Edgewise. The board's role is to monitor Edgewise Therapeutics' management team and ensure that shareholders' interests are well served. Edgewise Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Edgewise Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Koch, CEO President | ||
| Badreddin Edris, CoFounder Director | ||
| John Moore, General Counsel | ||
| Behrad Derakhshan, Chief Officer | ||
| Marc MD, Chief Officer | ||
| MD FACP, CoFounder Chairman | ||
| John JD, General Counsel | ||
| Alan Russell, Chief CoFounder | ||
| Michael Carruthers, Chief Officer |
Edgewise Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Edgewise Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.32 | ||||
| Return On Asset | -0.22 | ||||
| Current Valuation | 2.56 B | ||||
| Shares Outstanding | 94.69 M | ||||
| Shares Owned By Insiders | 0.46 % | ||||
| Shares Owned By Institutions | 99.53 % | ||||
| Number Of Shares Shorted | 6.39 M | ||||
| Price To Earning | 3.45 X | ||||
| Price To Book | 6.24 X | ||||
| EBITDA | (112.81 M) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Edgewise Stock Analysis
When running Edgewise Therapeutics' price analysis, check to measure Edgewise Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Edgewise Therapeutics is operating at the current time. Most of Edgewise Therapeutics' value examination focuses on studying past and present price action to predict the probability of Edgewise Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Edgewise Therapeutics' price. Additionally, you may evaluate how the addition of Edgewise Therapeutics to your portfolios can decrease your overall portfolio volatility.